Tracking a new lymphoma Drug's Real-World performance
NCT ID NCT07393204
Summary
This study is observing how well the drug epcoritamab works for patients with an aggressive type of lymphoma (DLBCL) that has returned or stopped responding to other treatments. It follows 150 patients in Italy who are already receiving the drug through a special access program, tracking their response to treatment and any side effects. The goal is to understand the drug's effectiveness and safety in everyday medical practice, outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Ospedale San Raffaele
Milan, Italy
Conditions
Explore the condition pages connected to this study.